Episode 45: ASCO 2023 - Gynaecologic Cancers

Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetuximab Soravtansine, a novel ADC with efficacy in ovarian cancer. Michael and Josh also discuss the Oval Study (ofranergene obadenovec) and immunotherapy in the DUO-O trial and Keynote 826. Not all trials are equal, and this OftIM ASCO special explores endpoints, hazard ratios and comparisons.